Two FDA-Cleared PLAC® Tests

As pioneers in the testing of Lp-PLA2, a validated marker of cardiovascular risk, we have a portfolio of commercially-available PLAC® Tests, the only two FDA-cleared tests to measure Lp-PLA2.

Capabilities and Product Portfolio for Growth

Our extensive capabilities, from development to commercialization, enable our evolution into a multi-product company delivering actionable information to healthcare providers for patient management.

Recent News

July 28, 2015

Diadexus and Mayo Clinic Join Forces on PLAC Activity Test to Improve Patient Care for Cardiovascular Diseases

July 7, 2015

Diadexus, Inc. Names William Hammond as Vice President of Sales